Alto Neuroscience (ANRO) Cash from Financing Activities (2023 - 2026)
Alto Neuroscience (ANRO) posted Cash from Financing Activities of $114.9 million for Q1 2026, up 129.03% sequentially from $50.2 million in Q4 2025, and up 1159.35% YoY from $9.1 million in Q1 2025.
Alto Neuroscience (ANRO) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Cash from Financing Activities for 4 years, with the latest figure at $114.9 million in Q1 2026.
- Quarterly Cash from Financing Activities rose 1159.35% year-over-year to $114.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $165.9 million (up 1517.04% YoY) and the FY2025 annual result came in at $60.1 million, down 55.72% from the prior year.
- Cash from Financing Activities rose to $114.9 million in Q1 2026 per ANRO's latest filing, from $50.2 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $134.6 million in Q1 2024 and troughed at -$234000.0 in Q2 2024.
- A 4-year average of $29.1 million and a median of $1.3 million in 2024 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities sank 358.82% in 2024, then soared 102318.37% in 2025.
- Over 4 years, Cash from Financing Activities stood at $43.1 million in 2023, then tumbled by 99.89% to $49000.0 in 2024, then jumped by 102318.37% to $50.2 million in 2025, then jumped by 129.03% to $114.9 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $114.9 million, $50.2 million, and $153000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | -273,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -273,000.00 |
| Jun 30, 2026 | -273,000.00 |
| Mar 31, 2026 | 114.94 Mn |
| Mar 31, 2026 | 114.94 Mn |
| Dec 31, 2025 | 50.19 Mn |
| Dec 31, 2025 | 50.19 Mn |
| Sep 30, 2025 | 153,000.00 |
| Sep 30, 2025 | 153,000.00 |
| Jun 30, 2025 | 613,000.00 |
| Jun 30, 2025 | 613,000.00 |
| Mar 31, 2025 | 9.13 Mn |
| Mar 31, 2025 | 9.13 Mn |
| Dec 31, 2024 | 49,000.00 |
| Dec 31, 2024 | 49,000.00 |
| Sep 30, 2024 | 1.32 Mn |
| Sep 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | -234,000.00 |
| Jun 30, 2024 | -234,000.00 |
| Mar 31, 2024 | 134.56 Mn |
| Mar 31, 2024 | 134.56 Mn |